Received Feb 19, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 324B2 | — |
boostrix expired dose administration (1.30.26 expiration vs 1.12.26 administration); This non-serious case was reported by a nurse via call center representative and described the occurrence of expired vaccine used in a adult male patient who received DTPa (Reduced antigen) (Boostrix) (batch number 324B2, expiry date 30-JAN-2026) for prophylaxis. On 12-FEB-2026, the patient received Boostrix. On 12-FEB-2026, an unknown time after receiving Boostrix, the patient experienced expired vaccine used (Verbatim: boostrix expired dose administration (1.30.26 expiration vs 1.12.26 administration)). The outcome of the expired vaccine used was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 13-FEB-2026 The patient was over 40 years old. The health care professional stated that they did not wish to provide the date of birth and initials.